Literature DB >> 19951373

Effect of everolimus on skin cancers in calcineurin inhihitor-treated heart transplant recipients.

Sylvie Euvrard, Pascale Boissonnat, Ana Roussoulières, Jean Kanitakis, Evelyne Decullier, Alain Claudy, Laurent Sebbag.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19951373     DOI： 10.1111/j.1432-2277.2009.01010.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN： 0934-0874            Impact factor:   3.782


× No keyword cloud information.
  7 in total

1.  Anaplastic large-cell lymphoma (ALK-negative)-related heart failure and recurrence after heart transplantation.

Authors:  Christopher Felicelli; Nicolas Lopez-Hisijos; Reeba Omman; Daniel Shepherd; Vijayalakshmi Ananthanarayanan; Ameet R Kini; Rhett P Ketterling; Joseph J Maleszewski; Elaine S Jaffe; Sucha Nand; Joshua Newman; Ashish Haryani; Max Liebo; Kamran M Mirza
Journal:  J Heart Lung Transplant       Date:  2020-07-07       Impact factor: 13.569

Review 2.  Skin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer?

Authors:  Edward K Geissler
Journal:  Transplant Res       Date:  2015-01-14

3.  Everolimus for compassionate use in multiple Basal cell carcinomas.

Authors:  Laura Eibenschutz; Delia Colombo; Caterina Catricalà
Journal:  Case Rep Dermatol Med       Date:  2013-09-23

Review 4.  Everolimus in heart transplantation: an update.

Authors:  Stephan W Hirt; Christoph Bara; Markus J Barten; Tobias Deuse; Andreas O Doesch; Ingo Kaczmarek; Uwe Schulz; Jörg Stypmann; Assad Haneya; Hans B Lehmkuhl
Journal:  J Transplant       Date:  2013-12-05

Review 5.  Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update.

Authors:  Hallvard Holdaas; Paolo De Simone; Andreas Zuckermann
Journal:  J Transplant       Date:  2016-10-11

6.  The CECARI Study: Everolimus (Certican®) Initiation and Calcineurin Inhibitor Withdrawal in Maintenance Heart Transplant Recipients with Renal Insufficiency: A Multicenter, Randomized Trial.

Authors:  Jan Van Keer; David Derthoo; Olivier Van Caenegem; Michel De Pauw; Eric Nellessen; Nathalie Duerinckx; Walter Droogne; Gábor Vörös; Bart Meyns; Ann Belmans; Stefan Janssens; Johan Van Cleemput; Johan Vanhaecke
Journal:  J Transplant       Date:  2017-02-20

7.  Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial.

Authors:  Claudia Sommerer; Barbara Suwelack; Duska Dragun; Peter Schenker; Ingeborg A Hauser; Björn Nashan; Friedrich Thaiss
Journal:  Trials       Date:  2016-02-17       Impact factor: 2.279
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.